Clinical Trial

A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will examine the safety and tolerability of single and multiple doses of IB-001, and will be conducted in two parts: Part A: SAD study in approximately 50 Healthy Volunteers (HV). Part B: MAD study in approximately 30 adult participants living with Chronic Hepatitis B (CHB).
Protocol Amendment History 1 change
notable Enrollment reduced: 90 -> 80 participants 2026-07-03
Trial Details
NCT Number NCT07389044
Lead Sponsor IntegerBio
Conditions Chronic Hepatitis B Virus Infection
Enrollment 80 participants
Start Date 2026-02-20
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-30